These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations. Miric A, Lombardi P, Sculco TP. Am J Orthop (Belle Mead NJ); 2000 Apr; 29(4):269-74. PubMed ID: 10784014 [Abstract] [Full Text] [Related]
23. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Haentjens P, De Groote K, Annemans L. Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714 [Abstract] [Full Text] [Related]
25. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. O'Brien BJ, Anderson DR, Goeree R. CMAJ; 1994 Apr 01; 150(7):1083-90. PubMed ID: 8137188 [Abstract] [Full Text] [Related]
27. [Assessment of complications of major orthopedic surgery: comparison of indobufen, calcium heparin, and low molecular heparin]. Borghi B, Bassi A, Grazia M, Feoli MA, Pignotti E. Minerva Anestesiol; 1996 Mar 01; 62(3):93-100. PubMed ID: 8767154 [Abstract] [Full Text] [Related]
31. The post-hospital discharge venous thrombosis risk of the orthopedic patient. Planes A, Vochelle N. Orthopedics; 1997 Feb 01; 20 Suppl():18-21. PubMed ID: 9048403 [Abstract] [Full Text] [Related]
32. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Howard AW, Aaron SD. Thromb Haemost; 1998 May 01; 79(5):902-6. PubMed ID: 9609217 [Abstract] [Full Text] [Related]
33. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery. Agnelli G, Sonaglia F. Semin Thromb Hemost; 1997 May 01; 23(2):143-8. PubMed ID: 9200338 [Abstract] [Full Text] [Related]
34. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. Nilsson PE, Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlund U, Nicolas S, Nylander G. Orthopedics; 1997 Feb 01; 20 Suppl():22-5. PubMed ID: 9048404 [Abstract] [Full Text] [Related]
37. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Hamulyák K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Thromb Haemost; 1995 Dec 01; 74(6):1428-31. PubMed ID: 8772214 [Abstract] [Full Text] [Related]
38. The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis. Warwick D, Rosencher N. Clin Appl Thromb Hemost; 2010 Aug 01; 16(4):394-405. PubMed ID: 20019020 [Abstract] [Full Text] [Related]